Clinical research
The primary objectives were non-inferior immunogenicity of NanoFlu compared to Sanofi’s Fluzone Quadrivalent based on several 28-day metrics.
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
The company said the decision to advance the CGRP receptor antagonist into late-stage studies followed a successful end-of-phase meeting with the U.S. Food and Drug Administration.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
Pfizer had a good day Wednesday with the announcement of positive results from two Phase III trials, one in moderate to severe atopic dermatitis and one in pneumococcal disease.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
PRESS RELEASES